Journal of biological response modifiers最新文献_第10页

Treatment of renal cell carcinoma with daily low-dose alpha-interferon. 每日低剂量干扰素治疗肾细胞癌。

Journal of biological response modifiers Pub Date : 1989-10-01

M E Marshall, W Simpson, K Butler, A Fried, M Fer

{"title":"Treatment of renal cell carcinoma with daily low-dose alpha-interferon.","authors":"M E Marshall, W Simpson, K Butler, A Fried, M Fer","doi":"","DOIUrl":"","url":null,"abstract":"While alpha-interferon has yielded objective tumor regressions in patients with metastatic renal cell carcinoma, such therapy is usually associated with significant toxicity often requiring dose modifications and/or cessation of therapy. In the absence of a clearly defined optimal dose and schedule for alpha-interferon, it appears reasonable to seek a means for improving the therapeutic index for this drug. We report the results of a pilot trial in which patients with renal cell carcinoma were treated with a daily low dose of alpha-interferon. Seventeen patients were treated with alpha-interferon (Roferon-A) at a dose of 1 million U subcutaneously daily. There were no exclusionary criteria for this pilot trial. Sixteen patients were evaluable for response and toxicity. Therapy was well-tolerated with no interruption of therapy for toxicity. No patient experienced the \"flu-like\" syndrome that is associated with higher doses, and there was no episode of granulocytopenia or thrombocytopenia. Four patients achieved a partial response (PR), with one PR persisting at 20 months. Sites of response included lung (two patients), liver (one patient), and bone (one patient). These results indicate that this regimen is well tolerated and can be expected to render objective responses. Formal Phase II trials are warranted in order to define the response rate for this regimen.","PeriodicalId":15063,"journal":{"name":"Journal of biological response modifiers","volume":"8 5","pages":"453-61"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13934244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody. 人唾液腺腺癌细胞系单克隆抗体:用链球菌制剂OK-432增强人唾液腺腺癌裸鼠体内抗体依赖细胞介导的细胞毒活性。

Journal of biological response modifiers Pub Date : 1989-10-01

R Kaji, H Yoshida, T Yanagawa, M Sato

{"title":"Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.","authors":"R Kaji, H Yoshida, T Yanagawa, M Sato","doi":"","DOIUrl":"","url":null,"abstract":"An IgG2a mouse monoclonal antibody (MoAb) to the human salivary gland adenocarcinoma cell line HSG, 5B/10, has been generated in our laboratory. In the current study, the antitumor effects mediated by MoAb 5B/10 in human salivary gland adenocarcinoma (HSG)-bearing nude mice or the antibody-dependent cell-mediated cytotoxicity (ADCC) against HSG cells using human peripheral blood mononuclear cells (PBMC) as effector cells were examined. In addition, effects of the streptococcal preparation OK-432 on the growth of HSG tumors or on the MoAb 5B/10-mediated cellular cytotoxicity were studied. MoAb 5B/10 mediated an ADCC reaction against HSG cells that were insensitive to NK cells but not to the reaction of antibody and complement-mediated cytotoxicity. The coexistence of MoAb 5B/10 and OK-432 caused marked augmentation of cytotoxic effects. Treatment of OK-432-stimulated PBMC with antiasialo Gm1 antiserum plus complement but not with silica particles resulted in a significant decrease of cytotoxic effects as compared with relevant controls. the nude mice inoculated intraperitoneally with HSG cells and treated with MoAb 5B/10, OK-432, or (especially) a combination of the two had significantly prolonged survival times as compared with untreated controls. Moreover, spleen cells from the tumor-bearing mice treated with OK-432 alone or a combination of MoAb 5B/10 and OK-432 were found to carry high levels of effector cell activity in the MoAb 5B/10-mediated cytotoxicity assay using HSG cells as targets.","PeriodicalId":15063,"journal":{"name":"Journal of biological response modifiers","volume":"8 5","pages":"488-500"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13696176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokine augmentation of human immunodeficiency virus type 1 (HIV-1) gp120-specific cellular cytotoxicity. 人类免疫缺陷病毒1型(HIV-1) gp120特异性细胞毒性的细胞因子增强

Journal of biological response modifiers Pub Date : 1989-10-01

K C Stine, D Bolognesi, K J Weinhold

引用次数: 0

Fragmentation of cellular DNA is a nonspecific indicator of responsiveness to tumor necrosis factor. 细胞DNA的断裂是对肿瘤坏死因子反应性的非特异性指标。

Journal of biological response modifiers Pub Date : 1989-10-01

B Y Rubin, S L Anderson, R M Lunn, G R Hellermann, L J Smith

引用次数: 0

Xanthine oxidase potentiation of reactive oxygen intermediates in isolated canine peripheral neutrophils. 犬外周中性粒细胞中活性氧中间体黄嘌呤氧化酶的增强作用。

Journal of biological response modifiers Pub Date : 1989-10-01

D F Gruber, K P O'Halloran, A M Farese

引用次数: 0

Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study. 人c -反应蛋白和三肽产生杀瘤效应细胞的比较研究。

Journal of biological response modifiers Pub Date : 1989-10-01

S Gautam, S Deodhar

{"title":"Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study.","authors":"S Gautam, S Deodhar","doi":"","DOIUrl":"","url":null,"abstract":"C-reactive protein (CRP) delivered in liposomes [CRP-multilamellar vesicles (MLV)] has been demonstrated to inhibit lung and liver metastases in C57 mice bearing the syngeneic tumors T241 fibrosarcoma and MCA-38 colon carcinoma, respectively. Also peritoneal exudate cells (PEC) from CRP-MLV-treated animals exhibited tumor inhibitory activity in the Winn neutralization assay, and the magnitude of this activity was comparable to that of PEC from muramyl tripeptide (MTP)-MLV-treated mice. The present studies were carried out to compare the mechanisms involved in generation of the tumoricidal effector cell by CRP-MLV and MTP-MLV. The antitumor activity of both CRP-MLV- and MTP-MLV-activated PEC was markedly inhibited by antimacrophage antiserum and complement in the Winn neutralization assay. Also, both activities were unaffected by treatment with anti-immunoglobulin antiserum and complement. However, antitumor activity of CRP-MLV-activated PEC was inhibited by anti-Thy 1.2 and antiasialo Gm 1 antisera in the presence of complement, whereas these reagents had no effect on MTP-MLV-activated PEC. Thus, the antitumor effect of MTP-MLV appears to be mediated principally by macrophages, whereas that of CRP-MLV may also involve other cells bearing T- and/or natural killer-cell markers.","PeriodicalId":15063,"journal":{"name":"Journal of biological response modifiers","volume":"8 5","pages":"560-9"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13933481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapy combining tumor necrosis factor with tumor-specific antibody against Meth A sarcoma. 肿瘤坏死因子联合肿瘤特异性抗体联合治疗甲胺磷A肉瘤。

Journal of biological response modifiers Pub Date : 1989-10-01

N Satomi, A Sakurai, R Haranaka, K Haranaka

引用次数: 0

Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2. 长期多次培养淋巴因子活化杀伤(LAK)细胞输注和重组人白细胞介素-2治疗晚期癌症患者。

Journal of biological response modifiers Pub Date : 1989-10-01

A Mittelman, S Savona, E Gafney, K O Penichet, B Y Lin, D Levitt, T Ahmed, Z A Arlin, P Baskind, D Needleman

{"title":"Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.","authors":"A Mittelman, S Savona, E Gafney, K O Penichet, B Y Lin, D Levitt, T Ahmed, Z A Arlin, P Baskind, D Needleman","doi":"","DOIUrl":"","url":null,"abstract":"Escalating doses of recombinant human interleukin-2 (rIL-2) were combined with long-term cultured rIL-2 activated killer cells to treat patients with disseminated melanoma, renal cell cancer, and colon cancer. Twenty-four patients were entered, 12 with renal cell cancer, 8 with colon cancer, and 4 with melanoma; 23 were evaluable for efficacy and toxicity. The (dose-related) toxicities were moderate to severe and consisted of fever, chills, rigors, weight gain, hypotension, mild confusion, elevation of liver enzymes and serum creatinine, thrombocytopenia, and eosinophilia. No cardiac events (arrhythmias or myocardial infarction) were recorded. None of the patients were admitted to the intensive care unit, and no deaths occurred. Two partial responses were observed, one at relatively low doses of rIL-2 in a patient with renal cell carcinoma and one at the highest dose level in a patient with malignant melanoma. The maximally tolerated dose level of rIL-2 for this study was 6 X 10(6) U/m2 i.v./day. The recommended dose for further studies is 3 X 10(6) U/m2 i.v./day in three divided doses.","PeriodicalId":15063,"journal":{"name":"Journal of biological response modifiers","volume":"8 5","pages":"468-78"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13933477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. 晚期恶性肿瘤患者皮下注射重组肿瘤坏死因子的一期临床试验。

Journal of biological response modifiers Pub Date : 1989-10-01

K W Zamkoff, N B Newman, A R Rudolph, J Young, B J Poiesz

{"title":"A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy.","authors":"K W Zamkoff, N B Newman, A R Rudolph, J Young, B J Poiesz","doi":"","DOIUrl":"","url":null,"abstract":"Nineteen patients with advanced cancer for which there was no effective standard therapy or whose disease was refractory to standard therapy were treated with recombinant tumor necrosis factor (rTNF). The rTNF was administered subcutaneously for 5 consecutive days every other week for 3 treatment weeks. The doses administered ranged from 5 micrograms/m2/day to 150 micrograms/m2/day. There was no intrapatient dose escalation. Systemic side effects of chills, fever, hypotension, nausea, vomiting, and headache were mild and self-limiting. At the maximum tolerated dose of 150 micrograms/m2/day, five of seven patients experienced moderate to severe thrombocytopenia. Mild rapid declines in total leukocyte count occurred within 60-90 min of administration of the drug, followed by a rise in the total leukocyte count by 120 min. When the total daily dose was administered in a single subcutaneous site, skin ulceration and necrosis occurred at the 100 micrograms/m2/day dose. By giving the total daily dose in two subcutaneous sites, the maximum tolerated dose increased to 150 micrograms/m2/day, and there was no further skin ulceration or necrosis. Skin necrosis occurred in the abdomen and thigh but not on the upper extremity at the 100 micrograms/m2/day dose given in a single site. There was no other significant organ toxicity. No rTNF was detectable in the serum even at the highest doses. No antibodies to TNF developed in any of the patients. The recommended dose of rTNF for Phase II trials given for 5 days subcutaneously is 150 micrograms/m2/day divided into two or more sites.","PeriodicalId":15063,"journal":{"name":"Journal of biological response modifiers","volume":"8 5","pages":"539-52"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13933480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunomodulating and antitumor activities of a synthetic lauroyltripeptide (RP 56 142). 合成月桂酰三肽的免疫调节和抗肿瘤活性。

Journal of biological response modifiers Pub Date : 1989-08-01

C Fizames, J Poirier, F Floc'h

引用次数: 0